Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.36 EUR | 0.00% |
|
0.00% | 0.00% |
11:03am | Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study | MT |
10:58am | CAC40: below 7600 pts, held back by the automotive sector | CF |
Sales 2024 * | 46.36B 49.59B 4,139B | Sales 2025 * | 49.93B 53.41B 4,458B | Capitalization | 113B 121B 10,133B |
---|---|---|---|---|---|
Net income 2024 * | 7.08B 7.58B 632B | Net income 2025 * | 8.69B 9.3B 776B | EV / Sales 2024 * | 2.6 x |
Net Debt 2024 * | 6.99B 7.48B 624B | Net Debt 2025 * | 2.37B 2.53B 211B | EV / Sales 2025 * | 2.32 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
13.1
x | Employees | - |
Yield 2024 * |
4.26% | Yield 2025 * |
4.48% | Free-Float | 87.13% |
Latest transcript on Sanofi
1 day | +18.46% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/19/01 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01/22/01 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/14/01 |
Lise Kingo
BRD | Director/Board Member | 62 | 28/20/28 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/20/22 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.61% | 811B | |
+43.68% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.77% | 246B | |
+2.62% | 225B | |
+12.65% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- SAN Stock
- 0O59 Stock